- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07943143
Histotripsy for Renal Cell Carcinoma (HRCC)
Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need
The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Study Design and Methodology
This study will enrol 15 patients with localised or metastatic renal cell carcinoma. Patients will be identified from clinic, and undergo a comprehensive evaluation, including imaging studies and laboratory tests, to confirm the diagnosis and assess their eligibility for histotripsy.
Procedure
Histotripsy will be performed by dedicated team of oncologist, urologist and radiologist who have undergone accredited training on Histotripsy aiming to achieve the best clinical outcomes and ensure patient safety. Patients are typically placed under general anaesthesia (GA) or monitored anaesthesia care (MAC) with real-time monitoring. The component of the Histotripsy machine that generates sound waves is positioned within a soft, flexible membrane filled with specially treated water, which rests on the patient's abdomen and facilitates the transmission of sound waves to the targeted tissue. The procedure will be delivered in a single session or multiple sessions by ultrasound, depending on the size and location of tumours.
Assessment
Patients will be invited to complete a questionnaire for pain score assessment before and after histotripsy.
Blood samples will be collected for clinical evaluation and laboratory tests at baseline, followed by 1-day, 30-day, 60-day, and 90-day after histotripsy, aligned with existing feasibility and trial schedules. Blood tests and cellular analysis such as complete blood profile, liver and renal function tests, tumour markers, immune markers and biomarkers etc. will be performed each time. Patients will be asked for consent for 15ml blood collection for the cellular analysis.
Serial post-histotripsy imaging (CT/MRI) will also be arranged. Imaging within 36-hour after histotripsy will be proceeded to confirm the ablation zone and assess complications. Post-procedure imaging at 1-, 3-, and 6-month will help to capture the sustainability of treatment effect, then per standard of care thereafter.
Admission and follow-up
Similar to other minimal invasive treatments, patients will be admitted one day prior, or on the day of procedure. After the procedure of histotripsy, patients may experience some discomfort in the treated area, but patients can often return to normal activities quickly. They could be discharged in few hours, or the next day after procedure depending on clinical conditions.
After discharge, follow-up consultations and assessments such as regular imaging and blood tests will be arranged accordingly.
Potential risk and discomfort
Blood drawn for laboratory tests can cause bruising at or near the site where the needle enters the vein and thus increase the risk of infection. Risks related to imaging scans will be explained prior to the procedures by the related doctors or medical professionals.
Procedure risk related to Histotripsy includes skin erythema or superficial burn injury, infection, bleeding, renal dysfunction, and abdominal wall injury or burn. Adverse post treatment event includes bleeding, infection, damage to surrounding structures etc. The medical team will monitor closely and response promptly.
Short-term effects
- Mild pain or soreness that usually responds to oral pain medication
- Low-grade fever and flu-like symptoms that typically resolve within 48 hours
- Temporary skin redness at the treatment site
- Mild abdominal discomfort
- Temporary changes in renal function tests
- Possible nausea or fatigue
- Transient haematuria
Potential serious complications
- Temporary decrease in kidney function
- Potential damage to surrounding organs (liver, lung, bowel, or stomach)
- Severe pain
- Need for extended hospital stay or additional treatment for serious complications
- Skin ulcer / necrosis requiring interventions
- Vascular thrombosis / dissection
Long-term complications
• Currently, there is no known long-term side effects from Histotripsy treatment. Ongoing research aims to evaluate the long-term outcomes.
In the event of complications arising from the study treatment, patients will be treated accordingly or referred for standard treatment and care.
Statistical analysis
Analysis will be performed for the 15 participants recruited, with basic demography (age, sex, medical history etc.), clinical evaluation, laboratory tests, imaging, treatment outcome with associated complication.
DATA AND BIOLOGICAL SAMPLES HANDLING
Patients will be invited to register on the Histotripsy (HistoSonics○R) Registry in Gleneagles Hospital Hong Kong for data collection. Collected personal and study data will be anonymised and stored in a password protected, encrypted database with the principal investigator and delegated staff in the long run. The principal investigator will be responsible for the safekeeping. Only investigators and delegated staff can have right to gain access to the data. All collected data and biological samples will be stored permanently for future review in histotripsy related research. Unused biological samples will be destroyed and discarded upon request, however, the results will remain a part of the overall research data if part of the sample has been proceeded.
Consent
Written voluntary consents will be obtained after full explanation of the study to patients before agreement of the histotripsy procedure.
Conflicts of interests
All investigators and funding bodies have no financial interests in the study.
Research ethics
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Patient data protection.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Professor Matthew Kin-liang CHIU, PhD
- Номер телефона: +852 22554352
- Электронная почта: mklc2@hku.hk
Места учебы
-
-
-
Hong Kong, Гонконг
- Рекрутинг
- Gleneagles Hospital Hong Kong
-
Контакт:
- Professor Matthew Kin-liang CHIU, PhD
- Номер телефона: +852 22554352
- Электронная почта: mklc2@hku.hk
-
Младший исследователь:
- Wing Hang Vince Lau, MBBS, FHKCR, FHKAM
-
Младший исследователь:
- Chi-Yan Albert Chan, MBBS, MS, FRCSEd, FCSHK, FHKAM
-
Младший исследователь:
- Justin Christopher Ng, MBBChBAO, LMCHK, MMED, FRCR
-
Младший исследователь:
- Pei Wayne Lam, MBBS, LMCHK, FRCSed, FCSHK
-
Младший исследователь:
- Cho Wing Bryan Li, MBBS, MRCP, FHKCP, FHKAM
-
Младший исследователь:
- Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
-
Младший исследователь:
- Lok Hei Clarence Leung, MBChB, FRCSEd, FCSHK, FHKAM
-
Младший исследователь:
- Hin Kay John Ngan, MBBS, FHKCS, FHKAM, FRCSE
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Age ≥ 18 years old
- Fit for general anaesthesia
- Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
- With or without distant metastases
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2
- Tumour visible and targetable by ultrasound with acceptable acoustic windows
- Adequate hematologic, hepatic, and renal function (eGFR ≥45mL/min, ≤14 days prior to the planned index procedure date).
Exclusion Criteria:
- Refusal to take part in clinical trial
- Not fit for general anaesthesia
- Poor general condition with limited life expectancy
- Uncontrolled coagulopathy
- The treatment of the tumour will not allow for an adequate margin as determined by the investigator
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison System
|
Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
To assess efficacy
Временное ограничение: 90 days post procedure
|
Successful treatment percentage at 90 days on MRI/CT post-procedure |
90 days post procedure
|
|
To assess treatment safety
Временное ограничение: At 30 days
|
Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher |
At 30 days
|
Вторичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Pain score assessment before and after histotripsy
Временное ограничение: At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
|
At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
|
Соавторы и исследователи
Спонсор
Соавторы
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Мужские мочеполовые заболевания
- Заболевания почек
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Новообразования по гистологическому типу
- Новообразования железистые и эпителиальные
- Аденокарцинома
- Урологические новообразования
- Карцинома
- Новообразования почек
- Карцинома, почечно-клеточная
Другие идентификационные номера исследования
- GHK-2026-005
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .